{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:35Z","timestamp":1794047495211,"version":"4.8.0"},"reference-count":48,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Age and sex have historically been associated with differences in the survival of patients with acute lymphoblastic leukemia (ALL). The NOPHO ALL2008 trial included patients aged 1-45 years with BCR::ABL1-negative B-precursor and T-cell ALL, but neither sex nor age was integrated into risk group allocation. Among 1,771 trial patients stratified into protocol- appropriate risk groups, we estimated the impact of age and sex on survival (even after relapse) and toxicities prospectively registered at 3-month intervals. In multivariate Cox regression analysis adjusted by sex, age group, and risk group, age but not sex was an independent risk factor for reduced 5-year event-free survival (EFS): hazard ratio=1.57 (95% confidence interval: 1.15-2.14) for patients 10-17.9 years, and 2.70 (95% confidence interval: 2.03-3.58) for patients 18-45 years, compared to patients &lt;10 years old at diagnosis. The overall 5-year pEFS was 0.83. For standard-risk patients (B-lineage, white cell count &lt;100x109\/L, no risk genetics, minimal residual disease day 29 &lt;0.1%), an inferior 5-year EFS was observed among patients 18-45 years (pEFS 0.78, P&lt;0.001) and 10-17.9 years (pEFS 0.86, P=0.002) compared to patients &lt;10 years at diagnosis (pEFS 0.93). For the intermediate-risk and high-risk groups, EFS was worse for patients 18-45 years compared to patients &lt;10 years: pEFS 0.69 versus 0.89 (P&lt;0.001) and pEFS 0.55 versus 0.71 (P=0.005), respectively. Osteonecrosis and veno-occlusive disease were associated with female sex in the standard-risk group, and age \u226510 years was associated with osteonecrosis, thrombosis, and pancreatitis in sex- and treatment-group-adjusted analyses. In conclusion, this study indicates that risk-grouping and\/or treatment-intensity criteria should differ across age groups and that age-adapted strategies to mitigate toxicities are needed.<\/jats:p>","DOI":"10.3324\/haematol.2024.286043","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:14:20Z","timestamp":1740021260000},"page":"1723-1735","source":"Crossref","is-referenced-by-count":3,"title":["Impact of age and sex on survival outcomes in patients aged 1-45 years with acute lymphoblastic leukemia treated according to the stratification used in the NOPHO ALL2008 trial"],"prefix":"10.3324","volume":"110","author":[{"given":"Tuomas Lahteenmaki","family":"Taalas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trausti","family":"Oskarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bendik","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Lepik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goda","family":"Vaitkevi\u010diene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olafur Gisli","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Toft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laimonas","family":"Gri\u0161kevi\u010dius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Hallbook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Palk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Wartiovaara-Kautto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Quist-Paulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Noren-Nystrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Vettenranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paivi M","family":"Lahteenmaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"77215","doi-asserted-by":"crossref","unstructured":"M\u00f6ricke A, Zimmermann M, Valsecchi MG. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016; 127(17):2101-2112.","DOI":"10.1182\/blood-2015-09-670729"},{"key":"77216","doi-asserted-by":"crossref","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016; 34(22):2591-2601.","DOI":"10.1200\/JCO.2015.64.6364"},{"key":"77217","doi-asserted-by":"crossref","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020; 105(11):2524-2539.","DOI":"10.3324\/haematol.2020.247031"},{"key":"77218","doi-asserted-by":"crossref","unstructured":"Toft N, Schmiegelow K, Klausen TW, Birgens H. Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008. Br J Haematol. 2012; 157(1):97-104.","DOI":"10.1111\/j.1365-2141.2011.09020.x"},{"key":"77219","doi-asserted-by":"crossref","unstructured":"Stock W, Johnson JL, Stone RM. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B study 19802. Cancer. 2013; 119(1):90-98.","DOI":"10.1002\/cncr.27617"},{"key":"77220","doi-asserted-by":"crossref","unstructured":"Goldstone AH, Richards SM, Lazarus HM. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII\/ECOG E2993). Blood. 2008; 111(4):1827-1833.","DOI":"10.1182\/blood-2007-10-116582"},{"key":"77221","doi-asserted-by":"crossref","unstructured":"Boissel N, Auclerc M-F, Lh\u00e9ritier V. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21(5):774-780.","DOI":"10.1200\/JCO.2003.02.053"},{"key":"77222","doi-asserted-by":"crossref","unstructured":"Stock W, La M, Sanford B. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112(5):1646-1654.","DOI":"10.1182\/blood-2008-01-130237"},{"key":"77223","doi-asserted-by":"crossref","unstructured":"Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol. 2015; 12(6):344-357.","DOI":"10.1038\/nrclinonc.2015.38"},{"key":"77224","doi-asserted-by":"crossref","unstructured":"Nor\u00e9n-Nystr\u00f6m U, Andersen MK, Barbany G. Genetic subtypes and outcome of patients aged 1 to 45 years old with acute lymphoblastic leukemia in the NOPHO ALL2008 trial. Hemasphere. 2023; 7(5):e883.","DOI":"10.1097\/HS9.0000000000000883"},{"key":"77225","doi-asserted-by":"crossref","unstructured":"Boissel N, Baruchel A. Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?. Blood. 2018; 132(4):351-361.","DOI":"10.1182\/blood-2018-02-778530"},{"key":"77226","doi-asserted-by":"crossref","unstructured":"Hangai M, Urayama KY, Tanaka J. Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adolescents and young adults. Biol Blood Marrow Transplant. 2019; 25(8):1597-1602.","DOI":"10.1016\/j.bbmt.2019.04.014"},{"key":"77227","doi-asserted-by":"crossref","unstructured":"Pieters R, Mullighan CG, Hunger SP. Advancing diagnostics and therapy to reach universal cure in childhood ALL. J Clin Oncol. 2023; 41(36):5579-5591.","DOI":"10.1200\/JCO.23.01286"},{"key":"77228","doi-asserted-by":"crossref","unstructured":"Schmiegelow K, Forestier E, Hellebostad M. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010; 24(2):345-354.","DOI":"10.1038\/leu.2009.251"},{"key":"77229","doi-asserted-by":"crossref","unstructured":"Toft N, Birgens H, Abrahamsson J. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018; 32(3):606-615.","DOI":"10.1038\/leu.2017.265"},{"key":"77230","doi-asserted-by":"crossref","unstructured":"Toft N, Birgens H, Abrahamsson J. Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2016; 96(2):160-169.","DOI":"10.1111\/ejh.12562"},{"key":"77231","doi-asserted-by":"crossref","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16(3):1141-1154.","DOI":"10.1214\/aos\/1176350951"},{"key":"77232","unstructured":"Gray B. Subdistribution analysis of competing risks. 2023. Publisher Full Text|"},{"key":"77233","unstructured":"R Core Team. R: a language and environment for statistical computing. 2021. Publisher Full Text|"},{"key":"77234","doi-asserted-by":"crossref","unstructured":"Liu L, Moke DJ, Tsai K-Y. A reappraisal of sex-specific cancer survival trends among adolescents and young adults in the United States. J Natl Cancer Inst. 2019; 111(5):509-518.","DOI":"10.1093\/jnci\/djy140"},{"key":"77235","doi-asserted-by":"crossref","unstructured":"Williams LA, Spector LG. Survival differences between males and females diagnosed with childhood cancer. JNCI Cancer Spectr. 2019; 3(2):pkz032.","DOI":"10.1093\/jncics\/pkz032"},{"key":"77236","doi-asserted-by":"crossref","unstructured":"Pui CH, Boyett JM, Relling MV. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999; 17(3):818-824.","DOI":"10.1200\/JCO.1999.17.3.818"},{"key":"77237","doi-asserted-by":"crossref","unstructured":"Chessells JM, Richards SM, Bailey CC, Lilleyman JS, Eden OB. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol. 1995; 89(2):364-372.","DOI":"10.1111\/j.1365-2141.1995.tb03313.x"},{"key":"77238","unstructured":"Gustafsson G, Kreuger A. Sex and other prognostic factors in acute lymphoblastic leukemia in childhood. Am J Pediatr Hematol Oncol. 1983; 5(3):243-250."},{"key":"77239","doi-asserted-by":"crossref","unstructured":"Lanning M, Garwicz S, Hertz H. Superior treatment results in females with high-risk acute lymphoblastic leukemia in childhood. Acta Paediatr. 1992; 81(1):66-68.","DOI":"10.1111\/j.1651-2227.1992.tb12081.x"},{"key":"77240","unstructured":"Bonaventure A, Harewood R, Stiller CA. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol. 2017; 4(5):e202-e217."},{"key":"77241","doi-asserted-by":"crossref","unstructured":"Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer. 2003; 97(9):2229-2235.","DOI":"10.1002\/cncr.11316"},{"key":"77242","doi-asserted-by":"crossref","unstructured":"Vora A, Goulden N, Wade R. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013; 14(3):199-209.","DOI":"10.1016\/S1470-2045(12)70600-9"},{"key":"77243","doi-asserted-by":"crossref","unstructured":"Lund B, \u00c5sberg A, Heyman M. Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer. 2011; 56(4):551-559.","DOI":"10.1002\/pbc.22719"},{"key":"77244","doi-asserted-by":"crossref","unstructured":"Meeske KA, Ji L, Freyer DR. Comparative toxicity by sex among children treated for acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group: acute toxicities among male and female patients with ALL. Pediatr Blood Cancer. 2015; 62(12):2140-2149.","DOI":"10.1002\/pbc.25628"},{"key":"77245","doi-asserted-by":"crossref","unstructured":"Wheeler K, Chessells JM, Bailey CC, Richards SM. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child. 1996; 74(2):101-107.","DOI":"10.1136\/adc.74.2.101"},{"key":"77246","doi-asserted-by":"crossref","unstructured":"Mattano LA, Devidas M, Nachman JB. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012; 13(9):906-915.","DOI":"10.1016\/S1470-2045(12)70274-7"},{"key":"77247","doi-asserted-by":"crossref","unstructured":"Brivio E, Cossio A, Borra D. Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort. Br J Haematol. 2022; 197(5):602-608.","DOI":"10.1111\/bjh.18147"},{"key":"77248","doi-asserted-by":"crossref","unstructured":"Stork LC, Matloub Y, Broxson E. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children\u2019s Oncology Group CCG-1952 clinical trial. Blood. 2010; 115(14):2740-2748.","DOI":"10.1182\/blood-2009-07-230656"},{"key":"77249","doi-asserted-by":"crossref","unstructured":"Stanulla M, Schaeffeler E, M\u00f6ricke A. Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia. 2021; 35(9):2650-2657.","DOI":"10.1038\/s41375-021-01203-7"},{"key":"77250","doi-asserted-by":"crossref","unstructured":"Toksvang LN, De Pietri S, Nielsen SN. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites. Pediatr Blood Cancer. 2017; 64(9)","DOI":"10.1002\/pbc.26519"},{"key":"77251","doi-asserted-by":"crossref","unstructured":"Mattano LA, Devidas M, Loh ML. Development of osteonecrosis and improved survival in B-ALL: results of Children\u2019s Oncology Group trial AALL0232. Leukemia. 2024; 38(2):258-265.","DOI":"10.1038\/s41375-023-02099-1"},{"key":"77252","doi-asserted-by":"crossref","unstructured":"Greiner J, Schrappe M, Claviez A. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019; 104(4):756-765.","DOI":"10.3324\/haematol.2018.194175"},{"key":"77253","doi-asserted-by":"crossref","unstructured":"Mogensen SS, Schmiegelow K, Grell K. Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica. 2017; 102(5):e175-e178.","DOI":"10.3324\/haematol.2016.160507"},{"key":"77254","doi-asserted-by":"crossref","unstructured":"Hossain MJ, Xie L, McCahan SM. Characterization of pediatric acute lymphoblastic leukemia survival patterns by age at diagnosis. J Cancer Epidemiol. 2014; 2014:865979.","DOI":"10.1155\/2014\/865979"},{"key":"77255","doi-asserted-by":"crossref","unstructured":"Pui C-H, Roberts KG, Yang JJ, Mullighan CG. Philadelphia chromosome-like acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2017; 17(8):464-470.","DOI":"10.1016\/j.clml.2017.03.299"},{"key":"77256","doi-asserted-by":"crossref","unstructured":"Kristj\u00e1nsd\u00f3ttir ER, Toksvang LN, Schmiegelow K, Rank CU. Prevalence of non-adherence and non-compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival. Eur J Haematol. 2022; 108(2):109-117.","DOI":"10.1111\/ejh.13711"},{"key":"77257","doi-asserted-by":"crossref","unstructured":"Forestier E, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology NOPHO. The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol. 2006; 28(8):486-495.","DOI":"10.1097\/01.mph.0000212972.90877.28"},{"key":"77258","doi-asserted-by":"crossref","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015; 373(16):1541-1552.","DOI":"10.1056\/NEJMra1400972"},{"key":"77259","doi-asserted-by":"crossref","unstructured":"Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017; 35(9):975-983.","DOI":"10.1200\/JCO.2016.70.7836"},{"key":"77260","doi-asserted-by":"crossref","unstructured":"Toksvang LN, Lee SHR, Yang JJ, Schmiegelow K. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia. 2022; 36(7):1749-1758.","DOI":"10.1038\/s41375-022-01591-4"},{"key":"77261","doi-asserted-by":"crossref","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003; 349(12):1157-1167.","DOI":"10.1056\/NEJMra035092"},{"key":"77262","doi-asserted-by":"crossref","unstructured":"Jensen KS, Oskarsson T, L\u00e4hteenm\u00e4ki PM. Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a Nordic population-based cohort study. Leukemia. 2022; 36(5):1274-1282.","DOI":"10.1038\/s41375-022-01540-1"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11948\/78083","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11948\/78612","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11948\/78083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:13Z","timestamp":1794046093000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286043","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}